1. A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia. Issue 4 (July 2019) Authors: DeMartinis, Nicholas; Lopez, Rene N.; Pickering, Eve H.; Schmidt, Christopher J.; Gertsik, Lev; Walling, David P.; Ogden, Adam Journal: Journal of clinical psychopharmacology Issue: Volume 39:Issue 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P4‐026: DEPRESSIVE SYMPTOMATOLOGY PREDICTS WILLINGNESS TO PARTICIPATE IN CLINICAL TRIALS. (1st July 2019) Authors: Park, Lovingly; Mendoza, Zyanya; Lee, Sophie; Kouhanim, Chanel; Tabizon, Jeanette; Gertsik, Lev; Semenova, Svetlana; Jhee, Stanford Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7S(2019)Part 24 Page Start: P1284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P4‐357: EFFECTS OF SCOPOLAMINE ON WORKING MEMORY TASK AND RESTING FUNCTIONAL CONNECTIVITY USING FMRI IN HEALTHY KOREAN SUBJECTS. (1st July 2014) Authors: English, Brett A.; Osimo, Niki; Korb, Alex; Bazih, Adam; Rodriguez, Cameron; Sotomayor, Byron; Gertsik, Lev; Ereshefsky, Larry Journal: Alzheimer's & dementia Issue: Volume 10:Supplement 4S(2014)Part 16 Page Start: P919 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Reduced memory and executive functioning significantly relates to participation in early phase clinical research in Alzheimer's disease: Human/Trial design. (7th December 2020) Authors: Park, Lovingly; Gertsik, Lev; Mendoza, Zyanya; Morris, Lydia; Aguilar, Claudia; Sherman, Molly; Semenova, Svetlana; Jhee, Stanford Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S43. A PROOF-OF-MECHANISM STUDY OF THE PDE10 INHIBITOR RG7203 IN PATIENTS WITH PROBING REWARD FUNCTIONS WITH IMAGING AND BEHAVIORAL APPROACHES. (1st April 2018) Authors: Umbricht, Daniel; Dukart, Jürgen; Abt, Markus; Tamburri, Paul; Chatham, Chris; Frank, Michael; Collins, Anne; Walling, David; Mofsen, Rick; Gruener, Daniel; Gertsik, Lev; Sevigny, Jeffrey Journal: Schizophrenia bulletin Issue: Volume 44(2018)Supplement 1 Page Start: S340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The H3 antagonist ABT‐288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers. (June 2014) Authors: Othman, Ahmed A.; Haig, George; Florian, Hana; Locke, Charles; Gertsik, Lev; Dutta, Sandeep Journal: British journal of clinical pharmacology Issue: Volume 77:Number 6(2014:Jun.) Page Start: 965 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. (January 2014) Authors: English, Brett A; Thomas, Kelan; Johnstone, Jack; Bazih, Adam; Gertsik, Lev; Ereshefsky, Larry Journal: Biomarkers in medicine Issue: Volume 8:Number 1(2014) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. (January 2014) Authors: English, Brett A; Thomas, Kelan; Johnstone, Jack; Bazih, Adam; Gertsik, Lev; Ereshefsky, Larry Journal: Biomarkers in medicine Issue: Volume 8:Number 1(2014) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗